Literature DB >> 16239290

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

Ronald N Jones1, Thomas R Fritsche, Yigong Ge, Koné Kaniga, Helio S Sader.   

Abstract

OBJECTIVES: To evaluate bactericidal activity of PPI-0903M and in vitro testing parameters for this compound.
METHODS: A total of 110 strains were tested to determine MIC and MBC values of PPI-0903M. MIC values were determined by reference broth microdilution whereas MBC was assessed by plating the broth from the MIC well and from those wells above the MIC for each organism onto appropriate drug-free growth media. Seventeen strains were tested by the kill-curve methodology to again evaluate the bactericidal activity of PPI-0903M. Broth microdilution results for 15 strains (in triplicate) were compared with the standard, reference method after modifying several testing parameters. Optimal disc content was assessed by testing seven reference strains with five PPI-0903M disc concentrations (5, 10, 30, 50 and 100 microg).
RESULTS: PPI-0903MMBC/MIC ratios were < or = 4 in 90% of strains tested. Kill-curve studies showed >99.9% killing at concentrations < or = 4x MIC within 8 to 24 h against staphylococci and Enterobacteriaceae tested. PPI-0903M MIC results were rarely influenced by the test or medium changes evaluated [high inoculum, low calcium or reduced pH (5.0)]. Human serum had no effect on in vitro antimicrobial activity of PPI-0903M. The 10 microg disc content would be recommended for optimal correlation of MIC breakpoints of < or = 1-4 mg/L.
CONCLUSIONS: PPI-0903M was generally bactericidal against tested species, and the MIC results were stable across numerous susceptibility test condition changes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239290     DOI: 10.1093/jac/dki362

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

3.  In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.

Authors:  Louis Saravolatz; Joan Pawlak; Leonard Johnson
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

4.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

5.  Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 6.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Yigong Ge; Donald Biek; Eric Batard; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

8.  In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Céline Vidaillac; Steve N Leonard; Helio S Sader; Ronald N Jones; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

9.  Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Authors:  Diego J Maselli; Juan F Fernandez; Christine Y Whong; Kelly Echevarria; Anoop M Nambiar; Antonio Anzueto; Marcos I Restrepo
Journal:  Infect Drug Resist       Date:  2012-02-01       Impact factor: 4.003

10.  Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability.

Authors:  Diane M Citron; Yumi A Warren; Kerin L Tyrrell; Ellie J C Goldstein
Journal:  ISRN Microbiol       Date:  2011-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.